Venous Reflux Clinical Trial
Official title:
ClosureFAST - Endovascular Radiofrequency Great Saphenous Vein Treatment Using a Catheter With an Integrated Heating Element
Verified date | February 2018 |
Source | Medtronic Endovascular |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to confirm that the ClosureFAST system can be used as an alternative to the current ClosurePlus catheter for treating the GSV and to accumulate pivotal data for optimization of the operating parameters.
Status | Completed |
Enrollment | 326 |
Est. completion date | May 2012 |
Est. primary completion date | May 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Age between 18 and 80 years of age at the time of enrollment - Symptomatic lower limb venous disease involving the GSV Exclusion Criteria: - Thrombosis in the vein segment to be treated - Known or suspected pregnancy or actively breast feeding at time of treatment |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Medtronic Endovascular |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Limbs Without Vein Occlusion | Defined as the absence of flow in the treated vein as documented on the post-procedure and follow-up Duplex Ultrasound (DU) scan. Flow which originates in the Saphenofemoral Junction (SFJ) and which measures < 3 cm in length, does not constitute a failure. | 6 Months | |
Primary | Percentage of Limbs Without Vein Occlusion | Defined as the absence of flow in the treated vein as documented on the post-procedure and follow-up DU scan. Flow which originates in the SFJ and which measures < 3 cm in length, does not constitute a failure. | 12 months | |
Primary | Percentage of Limbs Without Vein Occlusion | Vein occlusion is defined as the absence of flow in the treated vein as documented on the post-procedure and each successive follow-up DU scan. | 2 years | |
Primary | Percentage of Limbs Without Vein Occlusion | Defined as the absence of flow in the treated vein as documented on the post-procedure and follow-up DU scan. Flow which originates in the SFJ and which measures < 3 cm in length, does not constitute a failure. | 3 years | |
Primary | Percentage of Limbs Without Vein Occlusion | Defined as the absence of flow in the treated vein as documented on the post-procedure and follow-up DU scan. Flow which originates in the SFJ and which measures < 3 cm in length, does not constitute a failure. | 4 years | |
Primary | Percentage of Limbs Without Vein Occlusion | Defined as the absence of flow in the treated vein as documented on the post-procedure and follow-up DU scan. Flow which originates in the SFJ and which measures < 3 cm in length, does not constitute a failure. | 5 years | |
Primary | Percentage of Limbs Without Reflux in the Treated Vein Segment | No reflux in the vein segment treated. Reflux was defined as reversal flow >0.5s with subject standing or in reverse Trendelenburg position of at least 15° after distal augmentation. | 6 months | |
Primary | Percentage of Limbs Without Reflux in the Treated Vein Segment | No reflux in the vein segment treated. Reflux was defined as reversal flow >0.5s with subject standing or in reverse Trendelenburg position of at least 15° after distal augmentation. | 12 months | |
Primary | Percentage of Limbs Without Reflux in the Treated Vein Segment | No reflux in the vein segment treated. Reflux was defined as reversal flow >0.5s with subject standing or in reverse Trendelenburg position of at least 15° after distal augmentation. | 2 years | |
Primary | Percentage of Limbs Without Reflux in the Treated Vein Segment | No reflux in the vein segment treated. Reflux was defined as reversal flow >0.5s with subject standing or in reverse Trendelenburg position of at least 15° after distal augmentation. | 3 years | |
Primary | Percentage of Limbs Without Reflux in the Treated Vein Segment | No reflux in the vein segment treated. Reflux was defined as reversal flow >0.5s with subject standing or in reverse Trendelenburg position of at least 15° after distal augmentation. | 4 years | |
Primary | Percentage of Limbs Without Reflux in the Treated Vein Segment | No reflux in the vein segment treated. Reflux was defined as reversal flow >0.5s with subject standing or in reverse Trendelenburg position of at least 15° after distal augmentation. | 5 years | |
Secondary | CEAP (Clinical, Etiologic, Anatomic, and Pathophysiologic) Classification | Status of clinical signs and symptoms of lower limb venous disease as measured by CEAP Classification at baseline. The CEAP clinical Categories are as follows where C1 is of the least clinical concern and C6 is the worst stage; C1- Reticular and spider veins C2- Varicose veins C3- Varicose veins and leg swelling C4- Varicose veins and evidence of venous stasis skin changes C5- Varicose veins and a healed venous stasis ulceration C6- Varicose veins and an open venous ulceration Reference: Kistner RL, Eklof B, Masuda EM. Diagnosis of chronic venous disease of the lower extremities: The "CEAP" classification. Mayo Clinic Proc 1996;71:338-45. |
Baseline | |
Secondary | CEAP Classification | Status of clinical signs and symptoms of lower limb venous disease as measured by CEAP Classification at follow-up where C1 is the best and C6 is the worst in terms of clinical status. | 1 Week | |
Secondary | CEAP Classification | Status of clinical signs and symptoms of lower limb venous disease as measured by CEAP Classification at follow-up where C1 is the best and C6 is the worst in terms of clinical status. | 3 months | |
Secondary | CEAP Classification | Status of clinical signs and symptoms of lower limb venous disease as measured by CEAP Classification at follow-up where C1 is the best and C6 is the worst in terms of clinical status. | 12 months | |
Secondary | CEAP Classification | Status of clinical signs and symptoms of lower limb venous disease as measured by CEAP Classification at follow-up where C1 is the best and C6 is the worst in terms of clinical status. | 5 years | |
Secondary | Change in Venous Clinical Severity Score (VCSS) From Baseline to 5Y Follow-up | Status of clinical signs and symptoms of lower limb venous disease evaluated using standardized scales and subject responses to post-procedure standardized questions - VCSS Status from Baseline to 5 years. VCSS assesses 10 factors of venous disease whereby each factor is graded on a severity scale of 0-3 (least to worst). The higher the VCSS score the most severe the clinical signs and symptoms of venous disease are in a patient. VCSS improvement over time is presented by a decrease in VCSS total score (maximum score = 30; minimum score = 0). Reference: Rutherford RB, Padberg FT Jr, Comerota AJ, Kistner RL, Meissner MH, Moneta GL. Venous severity scoring: An adjunct to venous outcome assessment. J Vasc Surg 2000;31:1307-12. |
Baseline thru 5 years | |
Secondary | Visual Analog Pain Scale (VAS) | Status of clinical signs and symptoms of lower limb venous disease evaluated using standardized scales and subject responses to post-procedure standardized questions - VAS for pain scored from 0-10 with 10 being worst possible pain | 5 years | |
Secondary | Presence of Complications From Greater Saphenous Vein (GSV) Intervention | Number of limbs that presented with the listed complications and side effects resulting from the GSV intervention. | 1 Week | |
Secondary | Presence of Complications From GSV Intervention | Number of limbs that presented with the listed complications and side effects resulting from the GSV intervention. | 3 Months | |
Secondary | Presence of Complications From GSV Intervention | Number of limbs that presented with the listed complications and side effects resulting from the GSV intervention. | 12 months | |
Secondary | Presence of Complications From GSV Intervention | Number of limbs that presented with the listed complications and side effects resulting from the GSV intervention. | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05504070 -
Venclose digiRF System Post Market Study
|
N/A | |
Recruiting |
NCT05633277 -
Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections
|
N/A | |
Completed |
NCT02553720 -
The ATLANTIS Trial
|
N/A | |
Completed |
NCT04758728 -
Adrenaline Reduces Ecchymoses and Hematomas and Improves Quality of Life After Classic Saphenous Vein Stripping
|
N/A | |
Withdrawn |
NCT02936271 -
Efficacy of Vasculera in Prevention on Post-op Pain and Edema Following Lower Extremity Venous Treatment in the Outpatient Setting
|
N/A | |
Completed |
NCT02585726 -
Lake Washington Vascular VenaSeal™ Post-Market Evaluation (WAVES)
|
N/A | |
Active, not recruiting |
NCT04339075 -
Registry to Investigate the Efficacy and Safety of VenaBlock VeIn SEaling System for VaRicose Veins in SingApore
|
||
Recruiting |
NCT04146168 -
Lake Washington Vascular VenaSeal™ Post-Market Evaluation
|
||
Not yet recruiting |
NCT01901731 -
Pelvic Embolisation to Reduce Recurrent Varicose Veins - Primary
|
N/A | |
Completed |
NCT00509392 -
ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.
|
Phase 4 | |
Not yet recruiting |
NCT04774939 -
EVLA and Optimal Timing of Sclerotherapy
|
N/A | |
Not yet recruiting |
NCT04339088 -
High Intensity Focused Ultrasound in PAtients With Varicose Veins in Singapore
|
||
Completed |
NCT04006184 -
Retrospective Review of Saphenous Vein Incompetence: Venaseal Versus Endovenous Thermal Ablation
|
||
Not yet recruiting |
NCT01909024 -
Pelvic Embolisation to Reduce Recurrent Varicose Veins - Recurrent
|
N/A | |
Recruiting |
NCT03250247 -
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
|
N/A | |
Active, not recruiting |
NCT05707169 -
Comparison of Zero- and Two-centimeter Distance From Sapheno-femoral Junction in Laser Ablation of Varicose Vein
|
N/A | |
Active, not recruiting |
NCT03820947 -
VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT04384315 -
Efficacy and Safety of Endovenous Radio Frequency (EVRF) for Treatment of Varicose Veins in Singapore
|
||
Completed |
NCT01549860 -
Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers
|
N/A | |
Completed |
NCT03893201 -
A Singapore Venaseal Real World Post-Market Evaluation Study
|